Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
CRANBURY, N.J., June 07, 2017 -- Amicus Therapeutics, Inc. (Nasdaq:FOLD) announced today that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the upcoming Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Thursday, June 15, 2017 at 10:40 a.m. P.T.
A webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for epidermolysis bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
FOLD–G
CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino, IRC Senior Director, Investor Relations [email protected] (609) 662-5044
